Table 3. Open clinical trials combining LDFRT with chemotherapy in solid tumors.

Clinical trial parameters	Phase II
Site	Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme	Recurrent and Inoperable SCCHN	Recurrent Unresectable Locally Advanced SCCHN
Design	Temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle). LDFRT 0.5 Gy of radiation therapy twice daily with the first six 28-day cycles of temozolomide	No description available	Erbitux 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Mondays. Taxotere 20 mg/m2 IV once a week on Mondays on weeks 2 to 7. LDFRT 0.5 Gy per fraction BID at least 6 hours apart on Tuesday and Wednesday of weeks 2 to 7 for a total dose of 12 Gy
Duration	1 year	Not available	3.5 years
Recruitment	49	38	35
ClinicalTrials.gov identifier	NCT01466686	NCT01820312	NCT01794845

LDFRT, Low Doses Fractionated Radiation Therapy.